Magle Chemoswed Holding AB (publ) engages in researching, developing, and manufacturing in the areas of medicinal chemistry and pharmaceutical technology in Sweden, Switzerland, rest of Europe, the United States, Brazil, and internationally. It offers degradable starch microsphere and dextran products; and active pharmaceutical ingredients, as well as engages in the research, development, manufacture, market, and sale of diagnostics products to hospitals, clinics, and pharmacies; and contract development and manufacturing organization activities. The company also provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, an antipsychotic agent; and isradipine, a calcium channel blocker used to treat hypertension. In addition, it offers EmboCept S, a microsphere-based medical device used in vascular occlusion of liver and lung tumors; SmartGel, a non-allergenic hydrogel based on the company's microsphere technology; and SmartPAN, a medical device for the detection of pancreatic fluid leakage during open or minimally invasive surgical procedures. Further, the company is developing EmboCept M for the treatment of benign prostatic hyperplasia; EmboCept L for the treatment of uterine fibroids; SmartGel II, an advanced wound care hydrogel for the removal and prevention of wound biofilm; and SmartBone, an advanced formulation of microspheres in combination with active ingredients for stimulation of bone growth in surgical implant procedures. Additionally, it develops and produces stem cell-based therapies for investigational and GMP use; and provides consulting services in materials and solid phase analysis services. Magle Chemoswed Holding AB (publ) was founded in 1944 and is based in Malmö, Sweden.…
Xbrane clears the FDA, BioInvent seeks 430 Mkr and Genmab keeps surging – the Nordic Pulse | 2026:44
Magle Chemoswed Holding (STO: MAGLE) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 150 employees.
The shares were at 0.2540 SEK on 12 November 2026, down 98.7% over 52 weeks. Its 52-week range is 0.1200 SEK to 21.20 SEK: the price is 98.8% below the high and 111.7% above the low.
Its market capitalisation is 5.24M SEK.
Magle Chemoswed Holding reports return on equity of -84.1%, an operating margin of -48.1% and revenue up 39.2% year over year.
Its debt exceeds its cash by 341.91M SEK, a debt-to-equity ratio of 1.28. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 1.000 SEK is 293.7% above the current price.